https://www.selleckchem.com/products/ttk21.html
The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. To estimate the effect of remdesivir in blocking viral replication. We analysed nasopharyngeal normalized viral loads from 665 hospitalized patients included in the DisCoVeRy trial (NCT04315948; EudraCT 2020-000936-23), randomized to either standard of care (SoC) or SoC + remdesivir. We used a mathematical model to reconstruct viral kinetic profiles and estimate the antiviral efficacy of remdesivir in blocking viral replication. Additional analys
Like
Comment
Share
